Morgan Stanley is lowering its 2011e revenue on Teva Pharmaceutical Industries TEVA from $19.1B to $18.7B (vs. mgmt's $18.5-$19.5B) and 2011e EPS from $5.29 to $5.05 (midpoint of mgmt's $4.90-$5.20).
“We also lower our 2012e EPS from $6.04 to $5.78 to be more in-line with mgmt's $5.30-$5.86,” Morgan Stanley writes. “We are pleased that Ratiopharm integration is on track and that Teva suggested its 2015 revenue/EPS targets of $31B and $6.80-$7.52 could prove conservative since they excluded laquinimod. Mgmt. now expects laquinimod to be commercialized.”
Teva Pharmaceutical Industries currently trades at $51.47.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in